Pioneering a New Category of Targeted Cancer Therapeutics |

Targeting a Universal Tumor Metabolite: LACTATE

Tumors rely on aerobic glycolysis where they consume large amounts of glucose and convert it directly into lactate, even when oxygen is available. This process known as the Warburg Effect fuels rapid cell division and results in a high concentration of lactate being secreted, which becomes even higher in aggressive tumors.

The lactate concentration represented for "healthy tissues" is the max lactate found in tissues under healthy metabolic states.

Selective Release Inside the TME

The Alnair Lactate-reactive Nanoparticle (ALN) is composed of a Mesoporous Silica Nanoparticle (MSN) packed with a benefit agent covered by our proprietary lactate-reactive cap. The ALN is then capable of selectively releasing the benefit agent in the lactate-rich Tumor Micro Environment (TME). While many companies have failed to target the Warburg Effect via surrogate biomarkers, like pH-sensitive linkers, Alnair has become the first company to successfully target lactate itself.

In the Weeds: Our Proprietary Cap

We have engineered a lactate-reactive “cap” that is self-immolative in the presence of lactate. The ALN cap is composed of a peroxide-sensitive linker binding the surface of the MSN to cyclodextrin, which in turn is functionalized with an enzyme that oxidizes lactate. This is a tunable system that allows for changes in lactate sensitivity.

Pipeline Assets

Turning trusted first line cancer therapies into transformative precision-targeted treatments.

We are de-risking the ALN platform by reducing chemotherapy-related cardiotoxicity while expanding its therapeutic window via dose intensification.

In parallel, we aim to enable new treatment types (i.e. immunomodulatory agents) and help companies revive dead assets by bringing our safety profile to any API.

Indication: Breast, Ovarian, Sarcoma
Stage: Lead program, advancing to IND
Indication: Breast, Colorectal,
Stage: Target identification completed
Indication: Polydinamic therapy
Existing Market: Niche
Stage: Novel exploration, loaded